"Methods For Selective Sequencing Of Cancer Dna" in Patent Application Approval Process (USPTO 20240425930).

The patent application titled "Methods For Selective Sequencing Of Cancer DNA" by inventors Akavia, Forshew, Osborne, and Rosenfeld, assigned to Inivata Ltd., discusses the need for sensitive methods to detect minimal residual disease (MRD) in cancer patients after initial treatment. The methods described aim to increase sensitivity in detecting cancer-specific variants in a cost-efficient manner, utilizing large pools of oligonucleotides for personalized assays. By selectively sequencing target regions containing cancer-specific variants, these methods could improve early detection of relapse and guide personalized treatment decisions. [Extracted from the article]